Share Price, page-1546

Announcement - looking good for our "superior" drug NNZ-2591

Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced the appointment
of Liza A. Squires M.D. to the new position of Chief Medical Officer, based in the United States.
Dr Squires is a board certified physician in General Pediatrics and Neurology with Special
Competence in Child Neurology. Over the past 20 years, she has held positions of increasing
responsibilities in both early and late-stage development at Johnson and Johnson, Shire
Pharmaceuticals, Lumos Pharma, Aevi Genomic Medicine and Origin Biosciences. She has led
and contributed to multiple New Drug Applications resulting in global regulatory approvals and
has extensive experience in orphan drug development.
Dr Squires trained in general pediatrics at Yale University and did her residency in Child
Neurology at Massachusetts General Hospital.
Neuren CEO Jon Pilcher commented: “I am very pleased to welcome Liza at such an exciting
time for Neuren. Her ideal skills and experience in pediatric neurology and orphan drug
development will make a big difference to the team as we advance our ambitious plans for
NNZ-2591 in multiple indications.”